Skip to main content
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib
Published Web Location
https://doi.org/10.5070/D3241037931Abstract
Tofacitinib is a targeted inhibitor of janus kinase (JAK), currently approved for the treatment of rheumatoid arthritis. We present a patient on treatment withtofacitinib who had an episode of classic dermatomal herpes zoster followed months later by atypical chronic cutaneous ulcers also caused by herpes zoster.